Effects of an antithrombotic agent (MD-805) on progressing cerebral thrombosis.
The effects of the newly developed synthetic selective antithrombin agent MD-805 were examined in 11 patients with progressing cerebral thrombosis, as an open trial. Nine (82%) of 11 patients improved after 1 week of intravenous drip infusion. No hemorrhagic complications were observed during the therapy. These results suggest that MD-805 is a safe and effective agent for treatment of progressing cerebral thrombosis.
Kobayashi
S
S
Department of Internal Medicine, Shimane Medical University, Japan.
Kitani
M
M
Yamaguchi
S
S
Suzuki
T
T
Okada
K
K
Tsunematsu
T
T
D000368:Aged; D000990:Antithrombin III / Q000378:metabolism; D000991:Antithrombins / Q000008:administration & dosage / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D002542:Intracranial Embolism and Thrombosis / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D010875:Pipecolic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D012449:Safety; D013449:Sulfonamides; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D000991:Antithrombins; D010875:Pipecolic Acids; D013449:Sulfonamides; D000990:Antithrombin III; D001120:Arginine; D014568:Urokinase-Type Plasminogen Activator; C031942:argatroban